The sexual health products developer scaled up its retail share offer after strong demand, lifting total conditional fundraising to approximately £1.8 million.

The AIM-listed sexual health company reported a first-half operating loss of £1.20 million, down from £6.72 million a year earlier, as a settlement with former US partner Haleon boosted revenue and cash runway concerns intensified.

The AIM-listed sexual health group has secured regulatory clearance to launch a stronger-sensation version of its Eroxon erectile dysfunction gel across the EEA and UK, with US approval still pending.

Positive data from two studies bolster confidence in WSD4000, a potential first regulatory-approved OTC treatment for female sexual dysfunction, with a pivotal clinical trial targeted before year-end.

The small-cap firm terminated its Eroxon US partnership with Haleon, receiving a $1.9 million early termination fee, and signed a distribution agreement with Market Performance Group to take commercial control from 1 September.